Non-Malignant Hematology Treatment Center
The Non-Malignant Hematology Division at the Dana Farber/Brigham and Women's Cancer Center offers a broad range of clinical, research, teaching and administrative services. The clinical staff provides expert, conscientious care in the treatment of patients with blood disorders. Physicians are assisted by nurse practitioners with special expertise in the care of patients with blood disorders, including hemophilia and sickle cell disease.
Our clinical staff works closely with laboratory and radiology staff, oncologists, and primary care physicians. From diagnosis to continuing care, patients receive thorough and accessible management of their blood-related illness.
History
The Division has a rich history of contributions to hematology going back to the work of George Minot, MD, and William Murphy, MD, which led to the first treatment for pernicious anemia. Many prominent hematologists trained with us, including:
-
David G. Nathan, MD went on to become physician-in-chief at Children's Hospital Boston and then president of the Dana-Farber Cancer Institute.
-
David Rosenthal, MD later became director of Harvard University Health Services.
-
William Moloney, MD established treatment and research programs focused on leukemias and lymphomas in the late 1960s.
-
H. Franklin Bunn, MD and Robert Handin, MD made major advances into the research of hemoglobin function and with platelet biology and blood coagulation disorders in the 1970s. Handin served as president of the American Society of Hematology in 2002.
-
Thomas Stossel, MD was named American Cancer Society Clinical Research Professor in 1987, then was elected to the National Academy of Science in 1997.
-
Peter Marks, MD, PhD took over from Bruce M. Ewenstein, MD, PhD, as clinical director in 2000.
